OBJECTIVES: We explored the age-stratified correlates and correlations between high-risk human papillomavirus (HR-HPV) infection and cervical abnormalities in perimenopausal women. MATERIALS AND METHODS: Human papillomavirus testing and Pap smear screening were performed at baseline on 841 routinely screened women age 35 to 60 years in the HPV in perimenopause cohort. Demographic, behavioral, and medical information was collected through telephone-administered questionnaires. Descriptive analyses were used to examine the correlation between HR-HPV infection and cervical abnormalities by age. Logistic regression was used to determine correlates of HPV and abnormalities in women younger and older than 45 years. RESULTS: The prevalence of HPV, HR-HPV, and cervical abnormalities decreased significantly with increasing age, as did the correlation between HR-HPV and cervical abnormalities. The prevalence of HR-HPV was 50% among younger women with abnormalities but this decreased steadily to 20% HR-HPV detection among 50- to 54-year-old women, and no abnormalities were detected in 55- to 60-year-old women. Different correlates of HR-HPV infection and abnormalities were observed in women 45 years or older, a pattern not seen in younger women. CONCLUSIONS: Although the relative proportion of low-grade and high-grade abnormalities did not change with age, we saw a loss of concordance between HR-HPV detection and cytological abnormalities with increasing age. Current guidelines for cervical cancer screening group together all women age 30 years and older. Our data raise important questions about the interpretation of HPV and Pap test results in this age group and suggest that ongoing surveillance of HPV and cytology in cervical cancer screening programs consider a third age stratification among older women.
OBJECTIVES: We explored the age-stratified correlates and correlations between high-risk humanpapillomavirus (HR-HPV) infection and cervical abnormalities in perimenopausal women. MATERIALS AND METHODS:Human papillomavirus testing and Pap smear screening were performed at baseline on 841 routinely screened women age 35 to 60 years in the HPV in perimenopause cohort. Demographic, behavioral, and medical information was collected through telephone-administered questionnaires. Descriptive analyses were used to examine the correlation between HR-HPV infection and cervical abnormalities by age. Logistic regression was used to determine correlates of HPV and abnormalities in women younger and older than 45 years. RESULTS: The prevalence of HPV, HR-HPV, and cervical abnormalities decreased significantly with increasing age, as did the correlation between HR-HPV and cervical abnormalities. The prevalence of HR-HPV was 50% among younger women with abnormalities but this decreased steadily to 20% HR-HPV detection among 50- to 54-year-old women, and no abnormalities were detected in 55- to 60-year-old women. Different correlates of HR-HPV infection and abnormalities were observed in women 45 years or older, a pattern not seen in younger women. CONCLUSIONS: Although the relative proportion of low-grade and high-grade abnormalities did not change with age, we saw a loss of concordance between HR-HPV detection and cytological abnormalities with increasing age. Current guidelines for cervical cancer screening group together all women age 30 years and older. Our data raise important questions about the interpretation of HPV and Pap test results in this age group and suggest that ongoing surveillance of HPV and cytology in cervical cancer screening programs consider a third age stratification among older women.
Authors: Guglielmo Ronco; Jack Cuzick; Nereo Segnan; Silvia Brezzi; Francesca Carozzi; Stefania Folicaldi; Paolo Dalla Palma; Annarosa Del Mistro; Anna Gillio-Tos; Pamela Giubilato; Carlo Naldoni; Enzo Polla; Anna Iossa; Manuel Zorzi; Massimo Confortini; Paolo Giorgi-Rossi Journal: Eur J Cancer Date: 2007-01-12 Impact factor: 9.162
Authors: Philip E Castle; Jose Jeronimo; Mark Schiffman; Rolando Herrero; Ana C Rodríguez; M Concepción Bratti; Allan Hildesheim; Sholom Wacholder; L Rodney Long; Leif Neve; Ruth Pfeiffer; Robert D Burk Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk Journal: J Natl Cancer Inst Date: 2010-02-15 Impact factor: 13.506
Authors: Delphine Maucort-Boulch; Martyn Plummer; Philip E Castle; Franklin Demuth; Mahboobeh Safaeian; Cosette M Wheeler; Mark Schiffman Journal: Int J Cancer Date: 2010-02-01 Impact factor: 7.396
Authors: Meg Watson; Mona Saraiya; Vicki Benard; Steven S Coughlin; Lisa Flowers; Vilma Cokkinides; Molly Schwenn; Youjie Huang; Anna Giuliano Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Thomas C Wright; L Stewart Massad; Charles J Dunton; Mark Spitzer; Edward J Wilkinson; Diane Solomon Journal: Am J Obstet Gynecol Date: 2007-10 Impact factor: 8.661
Authors: Philip E Castle; Ana C Rodriguez; Carolina Porras; Rolando Herrero; Mark Schiffman; Paula Gonzalez; Allan Hildesheim; Robert D Burk Journal: Sex Transm Dis Date: 2007-11 Impact factor: 2.830
Authors: Jesse L Clark; Andres G Lescano; Kelika A Konda; Segundo R Leon; Franca R Jones; Jeffrey D Klausner; Thomas J Coates; Carlos F Caceres Journal: PLoS One Date: 2009-09-25 Impact factor: 3.240
Authors: Julia C Gage; William C Hunt; Mark Schiffman; Hormuzd A Katki; Li C Cheung; Jack Cuzick; Orrin Myers; Philip E Castle; Cosette M Wheeler Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-30 Impact factor: 4.254
Authors: Philip E Castle; Vânia R S Silva; Marcia E L Consolaro; Nádia Kienen; Lorna Bittencourt; Sandra M Pelloso; Edward E Partridge; Amanda Pierz; Camila B Dartibale; Nelson S Uchimura; Isabel C Scarinci Journal: Cancer Prev Res (Phila) Date: 2019-01-16
Authors: Julia C Gage; Hormuzd A Katki; Mark Schiffman; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Philip E Castle; Walter K Kinney Journal: Int J Cancer Date: 2014-09-02 Impact factor: 7.396
Authors: Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt Journal: Cancer Res Date: 2012-09-27 Impact factor: 12.701
Authors: Patti E Gravitt; Anne F Rositch; Michelle I Silver; Morgan A Marks; Kathryn Chang; Anne E Burke; Raphael P Viscidi Journal: J Infect Dis Date: 2012-12-12 Impact factor: 5.226
Authors: Rebecca M Brotman; Michelle D Shardell; Pawel Gajer; Doug Fadrosh; Kathryn Chang; Michelle I Silver; Raphael P Viscidi; Anne E Burke; Jacques Ravel; Patti E Gravitt Journal: Menopause Date: 2014-05 Impact factor: 3.310
Authors: Grazyna Stanczuk; Gwendoline Baxter; Heather Currie; James Lawrence; Kate Cuschieri; Allan Wilson; Marc Arbyn Journal: BMJ Open Date: 2016-04-25 Impact factor: 2.692